Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 91Neoplasm Metastasis 11Prostate Cancer Metastatic 4Oligometastatic Prostate Cancer 3Adenocarcinoma 3Radiation Injuries 2Prostatic Diseases 2Prostate CA 2Neoplasms 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Urologic Diseases 1Triple Negative Breast Neoplasms 1Stage IV Prostate Adenocarcinoma AJCC v7 1Stage I Prostate Adenocarcinoma 1Salivary Gland Neoplasms 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostate Adenocarcinoma 1PSA Level Greater Than 0.03 1Oligorecurrent and Oligoprogressive Prostate Cancer Patients 1Non-metastatic, Hormone naïve Prostate Cancer 1Neoplasm Recurrence, Local 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Hormone-Sensitive Prostate Cance 1Metastatic Castration-resistant Prostate Cancer 1Lymphatic Metastasis 1Intraprostatic Prostate Cancer 1Insulin Resistance 1Hormone Sensitive Prostate Cancer 1Genital Diseases, Male 1

Interventions

Cyclophosphamide 361Trastuzumab 352Paclitaxel 304Docetaxel 272Capecitabine 222Letrozole 221Carboplatin 185Doxorubicin 181Tamoxifen 157Radiotherapy 154Epirubicin 145Fulvestrant 143Anastrozole 139Surveys and Questionnaires 133Exercise 128pertuzumab 113Vinorelbine 110Blood Specimen Collection 109exemestane 106palbociclib 104Bevacizumab 104pembrolizumab 98Magnetic Resonance Spectroscopy 97Albumin-Bound Paclitaxel 87Gemcitabine 84Drug Therapy 83Lapatinib 78130-nm albumin-bound paclitaxel 72Neoadjuvant Therapy 71Cisplatin 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms × Androgen Antagonists × Clear all
NCT07340541 2026-05-20

EVOLVE-BDT

UNC Lineberger Comprehensive Cancer Center

Phase 2 Recruiting
700 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡